Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy

Authors

  • Paolo Gisondi Dipartimento di Medicina, Sezione di Dermatologia e Venereologia, Università di Verona - Italy
  • Francesco Loconsole Centro di Diagnosi e Cura della Psoriasi Clinica Dermatologica Universitaria Policlinico di Bari, Azienda Ospedaliera Universitaria Policlinico Consorziale Bari - Italy
  • Paola Raimondo MAA, Market Access Provider, Milano (MI) - Italy https://orcid.org/0000-0003-3316-4266
  • Roberto Ravasio HEOR &RWE Lead, Market Access Provider, Milano (MI) - Italy https://orcid.org/0000-0002-5477-1957

DOI:

https://doi.org/10.33393/grhta.2021.2258

Keywords:

Cost per responder, Plaque psoriasis, Risankizumab, Secukinumab, SSN

Abstract

Purpose: The objective of this analysis was to compare the cost per responder between risankizumab and secukinumab among patients with moderate-to-severe plaque psoriasis in Italy.

Methods: The clinical efficacy was assessed based on IMMerge study of published efficacy data as measured by Psoriasis Area and Severity Index response (PASI 90 and PASI 100) for risankizumab and secukinumab. The treatment cost was based on the number of administrations dispensed in the first (induction plus maintenance period) and the second (maintenance period only) year of treatment and the ex-factory price of each treatment. The cost per responder was adopted as a cost-effectiveness indicator.

Results: Independently of the PASI response (PASI 90 and PASI 100) used and the year of treatment considered, the cost per responder was consistently lower for risankizumab compared to secukinumab in all clinical measures. For example, considering the first-year costs and PASI 100, the cost per responder for risankizumab was € 24,506.83 compared to € 38,000.00 for secukinumab. The differences in the cost per responder between risankizumab and secukinumab increased when higher PASI response levels were considered.

Conclusion: This economic evaluation suggested that the cost per responder is consistently lower for risankizumab compared to secukinumab from the perspective of the Italian National Health Service in the treatment of moderate-to-severe plaque psoriasis.

References

Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50-59. https://doi.org/10.1111/bjd.19341 PMID:32594522 DOI: https://doi.org/10.1111/bjd.19341

Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354. https://doi.org/10.1101/cshperspect.a015354 PMID:25085957 DOI: https://doi.org/10.1101/cshperspect.a015354

Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994. https://doi.org/10.1016/S0140-6736(14)61909-7 PMID:26025581 DOI: https://doi.org/10.1016/S0140-6736(14)61909-7

Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78(5):827-851. https://doi.org/10.1086/503821 PMID:16642438 DOI: https://doi.org/10.1086/503821

Mui UN, Patel RR, Vangipuram R, Tyring SK. Tildrakizumab for Moderate-to-Severe Plaque Psoriasis. Skin Therapy Lett. 2019;24(6):1-4. PMID:31801012

Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891-895. PMID:20713823 DOI: https://doi.org/10.1001/archdermatol.2010.186

Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014;7:119-132. PMID:24790463 DOI: https://doi.org/10.2147/CCID.S44843

Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385. https://doi.org/10.1038/jid.2012.339 PMID:23014338 DOI: https://doi.org/10.1038/jid.2012.339

Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143(12):1493-1499. https://doi.org/10.1001/archderm.143.12.1493 PMID:18086997 DOI: https://doi.org/10.1001/archderm.143.12.1493

Pezzolo E, Cazzaniga S, Colombo P, Chatenoud L, Naldi L. Psoriasis Incidence and Lifetime Prevalence: Suggestion for a Higher Mortality Rate in Older Age-classes among Psoriatic Patients Compared to the General Population in Italy. Acta Derm Venereol. 2019;99(4):400-403. https://doi.org/10.2340/00015555-3130 PMID:30673108 DOI: https://doi.org/10.2340/00015555-3130

Vena GA, Altomare G, Ayala F, et al. Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Eur J Dermatol. 2010;20(5):593-598. PMID:20605768

Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850. https://doi.org/10.1016/j.jaad.2008.02.039 PMID:18423260 DOI: https://doi.org/10.1016/j.jaad.2008.02.039

Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009;60(3):394-401. https://doi.org/10.1016/j.jaad.2008.10.062 PMID:19231638 DOI: https://doi.org/10.1016/j.jaad.2008.10.062

Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(suppl 2):1-70. https://doi.org/10.1111/j.1468-3083.2009.03389.x PMID:19712190 DOI: https://doi.org/10.1111/j.1468-3083.2009.03389.x

Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774-790. https://doi.org/10.1111/jdv.14114 PMID:28244153 DOI: https://doi.org/10.1111/jdv.14114

Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies. Clin Dermatol. 2010;28(1):67-72. https://doi.org/10.1016/j.clindermatol.2009.03.001 PMID:20082954 DOI: https://doi.org/10.1016/j.clindermatol.2009.03.001

Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933-943. https://doi.org/10.1038/jid.2009.391 PMID:20043014 DOI: https://doi.org/10.1038/jid.2009.391

de Carvalho AVE, Duquia RP, Horta BL, Bonamigo RR. Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: a systematic review and meta-analysis of randomized clinical trials. Drugs R D. 2017;17(1):29-51. https://doi.org/10.1007/s40268-016-0152-xPMID:27838901 DOI: https://doi.org/10.1007/s40268-016-0152-x

Boehncke W-H, Brembilla NC. Unmet needs in the field of psoriasis: pathogenesis and treatment. Clin Rev Allergy Immunol. 2018;55(3):295-311. https://doi.org/10.1007/s12016-017-8634-3 PMID:28780731 DOI: https://doi.org/10.1007/s12016-017-8634-3

Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213-220. https://doi.org/10.1111/jdv.14007PMID:27739123 DOI: https://doi.org/10.1111/jdv.14007

Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645-653. https://doi.org/10.1016/j.jaci.2017.07.004 PMID:28887948 DOI: https://doi.org/10.1016/j.jaci.2017.07.004

Risankizumab RCP. Accesso Marzo 2020. Disponibile su: https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_it.pdf

Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650-661. https://doi.org/10.1016/S0140-6736(18)31713-6 PMID:30097359 DOI: https://doi.org/10.1016/S0140-6736(18)31713-6

Reddy V, Yang EJ, Myers B, Liao W. Clinical evaluation of risankizumab-rzaa in the treatment of plaque psoriasis. J Inflamm Res. 2020;13:53-60. https://doi.org/10.2147/JIR.S215196PMID:32158251 DOI: https://doi.org/10.2147/JIR.S215196

Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy versus treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649-658. https://doi.org/10.1001/jamadermatol.2020.0723 PMID:32267471 DOI: https://doi.org/10.1001/jamadermatol.2020.0723

CADTH Common Drug Review. Clinical Review Report: Risankizumab (Skyrizi) (AbbVie) Indication: For the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 2019.

Secukinumab RCP. Accesso Marzo 2020. Disponibile su: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_it.pdf

Gooderham M, Pinter A, Zheng J, Zhao Y, Kaufmann C, Strober B. Long-Term, Durable, Absolute Psoriasis Area and Severity Index Improvement of Risankizumab Treatment: An Interim Integrated Analysis of Patients with Moderate-to-Severe Plaque Psoriasis. Abstract 29th European Academy of Dermatology and Venereology 29-31 Oct.

Elewski B, Rich P, Crowley J, et al. Efficacy and Safety of Long-Term Risankizumab Treatment for Nail, Scalp, and Palmoplantar Psoriasis: An Interim Analysis from the Open-Label Extension LIMMitless Trial. Abstract 29th European Academy of Dermatology and Venereology 29-31 Oct.

G.U. serie generale n° 154 del 30 giugno 2021.

AIES. Associazione Italiana di Economia Sanitaria. Proposte di linee guida per la valutazione economica degli interventi sanitari. PharmacoEcon Ital Res Artic. 2009;11(2):89-93. DOI: https://doi.org/10.1007/BF03320660

Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis. A meta-analysis. JAMA Dermatol. 2020;156(3):258-269. https://doi.org/10.1001/jamadermatol.2019.4029 PMID:32022825 DOI: https://doi.org/10.1001/jamadermatol.2019.4029

Yasmeen N, Sawyer LM, Malottki K, Levin L-A, Apol ED, Jemec GB. Targeted therapies for patients with moderate-to severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. J Dermatolog Treat. 2020;1-15. https://doi.org/10.1080/09546634.2020.1743811. PMID: 3220244 DOI: https://doi.org/10.1080/09546634.2020.1743811

Megna M, Di Costanzo L, Argenziano G, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019;19(8):855-861. https://doi.org/10.1080/14712598.2019.1622678 PMID:31140882 DOI: https://doi.org/10.1080/14712598.2019.1622678

Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507-1514. https://doi.org/10.1111/jdv.14878 PMID:29444376 DOI: https://doi.org/10.1111/jdv.14878

Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831-839. https://doi.org/10.1016/S0140-6736(19)31773-8PMID:31402114 DOI: https://doi.org/10.1016/S0140-6736(19)31773-8

Zhang M, Carter C, Olson WH, et al. Patient Preference for Dosing Frequency Based on Prior Biologic Experience. J Drugs Dermatol. 2017;16(3):220-226. PMID:28301617

Published

2021-09-06

How to Cite

1.
Gisondi P, Loconsole F, Raimondo P, Ravasio R. Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy. Grhta [Internet]. 2021 Sep. 6 [cited 2021 Sep. 22];8:120-3. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/2258

Issue

Section

Original Research Article

Most read articles by the same author(s)

1 2 3 4 > >>